CTOs on the Move

Chesapeake IRB

www.chesapeakeirb.com

 
Chesapeake IRB and its Canadian affiliate, IRB Services, have been in business since 1993. They have established a reputation for excellence that is based on quality work, efficient processes, and excellent customer service. Chesapeake IRB`s schedule of 5 weekly meetings, daily expedited review capability, 4 day turnaround for protocols and 24-hour turnaround for Principal Investigators (PIs) has helped our clients become more competitive for industry sponsored studies; including Phase I research. While the majority of our studies are biomedical or device related, we have a broad range of social/behavioral studies that are often government or foundation funded. We work with you ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Broadmoor

Broadmoor is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LKIS Corporation

LKIS Corporation is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ogden Regional Medical Center

Ogden Regional Medical Center is a Ogden, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Garfield Park

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.